Novo-Nordisk ADR repsg 1 B Stock
StockStockPrice
Historical dividends and forecast
Novo-Nordisk ADR repsg 1 B has so far distributed $1.447 in 2024. The next dividend will be paid on 02.04.2025
CHART BY
Frequently asked questions
What is Novo-Nordisk ADR repsg 1 B's market capitalization?
What is Novo-Nordisk ADR repsg 1 B's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Novo-Nordisk ADR repsg 1 B?
What are the analyst ratings and target price for Novo-Nordisk ADR repsg 1 B's stock?
What is Novo-Nordisk ADR repsg 1 B's revenue over the trailing twelve months?
What is the EBITDA for Novo-Nordisk ADR repsg 1 B?
What is the free cash flow of Novo-Nordisk ADR repsg 1 B?
What is the 5-year beta of Novo-Nordisk ADR repsg 1 B's stock?
How many employees does Novo-Nordisk ADR repsg 1 B have, and what sector and industry does it belong to?
What is the free float of Novo-Nordisk ADR repsg 1 B's shares?
Financials
Market Cap
$381.50B5Y beta
0.87EPS (TTM)
$2.93Free Float
3.14BP/E ratio (TTM)
38.41Revenue (TTM)
$37.63BEBITDA (TTM)
$18.47BFree Cashflow (TTM)
$3.51BPricing
Analyst Ratings
The price target is $136.33 and the stock is covered by 28 analysts.
Buy
18
Hold
8
Sell
2
Information
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
69,260
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker